Processing...
Clinical Trials for Rectal Cancer
Search
Search
There are 226 active trials for advanced/metastatic rectal cancer.
Click on a trial to see more information.
226 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with advanced, incurable non-CNS solid tumors after progression on or intolerance to systemic therapy receive oral ETX-19477, an investigational PARG inhibitor that disrupts DNA damage repair. Enrollment preferentially considers tumors with loss-of-function BRCA2 mutations; treatment is given as monotherapy in dose-escalation and expansion cohorts.
ClinicalTrials.gov ID: NCT06395519
TrialFetch AI summary: Patients with metastatic HER2-positive breast cancer progressing after trastuzumab deruxtecan receive trastuzumab plus physician-selected chemotherapy with or without evorpacept, an investigational CD47 blocker that promotes macrophage engulfment of cancer cells. A separate substudy combines evorpacept with cetuximab and FOLFIRI for left-sided, microsatellite-stable, RAS/BRAF wild-type metastatic colorectal cancer progressing after first-line oxaliplatin, with no prior anti-EGFR therapy or irinotecan.
ClinicalTrials.gov ID: NCT07007559
TrialFetch AI summary: Adults with unresectable or metastatic mismatch repair–proficient colorectal cancer or pancreatic ductal adenocarcinoma (PDAC) and a vaccine-covered KRAS mutation receive a mutant KRAS long-peptide vaccine with poly-ICLC, plus balstilimab (anti-PD-1) and botensilimab (Fc-engineered anti-CTLA-4). Cohorts include patients after 4–6 months of first-line chemotherapy and a PDAC cohort allowing up to three prior regimens, including a KRAS inhibitor.
ClinicalTrials.gov ID: NCT06411691
TrialFetch AI summary: Adults with advanced, measurable solid tumors and ECOG performance status 0–2 receive intravenous DM002 every 21 days in dose-escalation or expansion cohorts. DM002 is an investigational bispecific antibody–drug conjugate targeting MUC1 and HER3 with a topoisomerase I inhibitor payload; patients previously treated with a topoisomerase I–payload ADC are generally excluded.
ClinicalTrials.gov ID: NCT06751329
TrialFetch AI summary: Adults with selected advanced or metastatic solid tumors receive oral temozolomide plus tuvusertib (M1774), an investigational ATR inhibitor that disrupts the DNA-damage response. The expansion cohort is limited to previously treated, MGMT promoter-hypermethylated, mismatch repair-proficient/microsatellite-stable metastatic colorectal cancer; prior temozolomide or ATR inhibitor therapy is excluded.
ClinicalTrials.gov ID: NCT05691491
TrialFetch AI summary: Adults with unresectable or metastatic colorectal cancer or metastatic pancreatic ductal adenocarcinoma receive oral RMC-6236, a multiselective active-RAS inhibitor, combined with fluorouracil-based chemotherapy and bevacizumab, cetuximab with or without mFOLFOX6, or gemcitabine plus nab-paclitaxel. In RAS G12D-mutant cohorts, the active-RAS G12D inhibitor RMC-9805 is given with or without RMC-6236 alongside the corresponding regimens.
ClinicalTrials.gov ID: NCT06445062
Phase I Trial of ZEN003694 (ZEN-3694) in Combination With Capecitabine in Patients With Solid Tumors
TrialFetch AI summary: Adults with metastatic or unresectable solid tumors that progressed after fluoropyrimidine-containing standard therapy receive oral ZEN-3694, an investigational BET protein inhibitor, plus oral capecitabine. Dose expansion is limited to colorectal cancer.
ClinicalTrials.gov ID: NCT05803382
TrialFetch AI summary: Adults with refractory or relapsed BRAF V600E–mutant metastatic colorectal cancer who have progressed after systemic therapy and previously tolerated cetuximab plus encorafenib receive those agents with investigational ZEN-3694, a BET bromodomain inhibitor. The study evaluates dosing and safety of the three-drug combination.
ClinicalTrials.gov ID: NCT06102902
TrialFetch AI summary: Adults with measurable, microsatellite-stable, KRAS-mutant metastatic colorectal cancer who have progressed on, cannot tolerate, or cannot receive fluoropyrimidine, oxaliplatin, and irinotecan receive botensilimab (an Fc-engineered anti-CTLA-4 antibody) plus balstilimab (an anti-PD-1 antibody), high-dose IV vitamin C, and a fasting-mimicking diet. Prior anti-PD-1 or anti-CTLA-4 therapy and current diabetes are exclusions.
ClinicalTrials.gov ID: NCT06336902
TrialFetch AI summary: Adults with measurable, unresectable or metastatic colorectal adenocarcinoma, ECOG 0–2, and no prior chemotherapy or antiangiogenic therapy may enroll; MSI-H/dMMR disease is excluded. Treatment adds oral emavusertib, an investigational IRAK4/FLT3 inhibitor, to first-line FOLFOX plus bevacizumab, with bevacizumab starting in cycle 1 or 2.
ClinicalTrials.gov ID: NCT06696768